COVID-19 in THORACIC ONCOLOGY PATIENTS

Erin M. Bange, MD
Hematology/Oncology Fellow PGY-4

5.26.20
WHAT ARE WE IN FOR?

› Part I – Important background data
› Part II – Important Articles
› Part III – Available guidelines
PART I – BACKGROUND
WHAT IS A PANDEMIC?

› A global outbreak of a novel virus which can infect people easily and spread from person to person in an efficient and sustained way.

› What affects the impact of a pandemic?
  › Clinical Severity
  › Transmissibility
WHAT IS THE SARS-COV-2?

› Member of the Coronaviridae family
HOW IS IT SPREAD?

› Spread through respiratory tract by droplets, respiratory secretions, and direct contact
  › Half life of aerosols ~ 1.1 hours, steel 5.6 hours, plastic 6.8 hours
› Virus RNA has been identified in samples from stool, GI tract, saliva, tears, semen, and urine
  › Fecal oral transmission has not been ruled out
› Median incubation period is reported to be 3-5 days (range 1-14 days)
› 95% experience symptoms by day 12.5 of contact
› Asymptomatic cases are common, and patients can transmit virus prior to symptom development
  › Infectiousness begins 2.3 days before symptom onset
› WHO estimates R0 to be 2.0-2.5
Clinical presentations can range from asymptomatic to severe respiratory failure

- In China
  - 81% mild
  - 14% severe
  - 05% critical

Primary symptoms
- Fever, cough, shortness of breath

Additional common symptoms
- Myalgias, fatigue, sore throat, nausea/vomiting, diarrhea, headache, anosmia, dysgeusia
- GI symptoms frequently occur prior to respiratory symptoms

Some patients have GI symptoms prior to fever/respiratory symptoms

Spectrum of neurological symptoms has been described ranging from CVA, skeletal muscle injury, headache, depressed consciousness, dizziness, seizure

---

**Table 2 Clinical Symptoms associated with COVID-19.**

<table>
<thead>
<tr>
<th>Clinical types</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild type</td>
<td>nonpneumonia or mild pneumonia</td>
</tr>
<tr>
<td>Severe type</td>
<td>dyspnea, respiratory frequency ≥ 30/min, blood oxygen</td>
</tr>
<tr>
<td></td>
<td>saturation ≤ 93%, partial pressure of arterial oxygen to fraction</td>
</tr>
<tr>
<td></td>
<td>of inspired oxygen ratio &lt; 300, and/or lung infiltrates &gt;50% within 24 to 48 hours</td>
</tr>
<tr>
<td>Critical type</td>
<td>respiratory failure, septic shock, and/or multiple organ dysfunction or failure</td>
</tr>
</tbody>
</table>
Current standard is nucleic acid detection via samples from nasopharyngeal swabs by real time PCR
- Accuracy is dependent on specimen collection, pre-test probability, and timing since onset of symptoms
- False negative rates are higher earlier in the disease course, repeat testing should be considered in the right clinical scenario
- Sensitivity and specificity assessments vary based on the specific assay, how it is processed, and whether best practices were followed

Rapid fluorescent immunoassay antigen detection
- Test results in 15 min
- Detects SARS-COV-2 nucleocapsid protein antigen
- Sensitivity 80% of PCR, negative predictive value ~88%, 100% specificity

Serology
- Reflects prior exposure and cannot be used to independently diagnose current infection
- Can be helpful in evaluate late sequelae (i.e. “covid toes syndrome”) when RT-PCR can be negative
- May cross react with other human coronaviruses

CT scans
- Can increase sensitivity when added to RT-PCR
- Can also be done alone if RT-PCR not available
- Sensitivity of CT in suspected patients was found to be 97% based on positive RT-PCR

PET/CT
- Case series from Italy have shown that asymptomatic patients can have signs of interstitial pneumonia with FDG uptake and later develop COVID19
WHAT ARE THE IMAGING FINDINGS?

- All lung segments can be involved, slight predilection for the RLL
- 79% of patients had bilateral lung involvement
- 54% showed peripheral distribution
- 44% showed diffuse distribution
- Most common patterns
  - 65% GGO
  - 81% Ill defined margins
  - 35% Smooth or irregular interlobular septal thickening
  - 47% Air bronchograms
  - 10% Crazy-paving pattern
  - 32% thickening of adjacent pleura


group 1 (scan before symptom onset; n=15),
group 3 (scan >1 week to 2 weeks after symptom onset; n=30), and
group 4 (scan >2 weeks to 3 weeks after symptom onset; n=15).

Figure 5 Transverse thin-section serial CT scans from a 77-year-old man
Radiation pneumonitis and immunotherapy induced pneumonitis can often present and appear like COVID-19 pneumonia on imaging studies.

The Chinese guidelines recommend a multidisciplinary team of radiologists, radiation oncologists, medical oncologists, and infectious disease physicians to help triage these patients when diagnostics are confounding.

Tumor progression, obstructive pneumonia, lymphangitic metastases, cancer associated pleural effusions can all cause fevers and associated imaging findings.

Do not forget cancer associated medical conditions in our differential diagnosis.

Pulmonary embolism, CHF, myocarditis, other viral/bacterial/fungal causes of pneumonia.

Co-infection with other viral pneumonias as well as bacterial super-infections have been reported and are associated with more serious illness.
WHAT IS SEEN UNDER THE MICROSCOPE?

- Two cases of asymptomatic patients, undergoing lobectomy for lung cancer, had findings consistent with exudative and proliferative phases of acute lung injury.
- Postmortem biopsies are consistent with diffuse alveolar damage and organizing pneumonia.


Histologic changes from case 1. ( ) Proteinaceous exudates in alveolar spaces, with granules; ( ) scattered large protein globules (arrows); ( ) intra-alveolar fibrin with early organization, mononuclear inflammatory cells, and multinucleated giant cells; ( ) hyperplastic pneumocytes, some with suspected viral inclusions (arrow).
HOW DO I MANAGE THESE PATIENTS?

- Implementation of infection control practices
- Oxygen support, when needed, favoring non-aerosolizing tools
  - Limit non-invasive mechanical ventilation and high-flow nasal cannula
- Minimize steroids, unless being used for alternative diagnosis (sepsis, ARDs) due to concern for increased viral shedding
- Prophylaxis for venous thrombosis, due to increased thrombotic risk in these patients
- Consider non-intubated hypoxemic patients to assume a prone position when practical
- Ongoing studies are assessing the role of various pharmacologic and immunologic interventions
  - Interim analysis of a placebo controlled RCT of remdesivir involving 1063 patients
    - Patients on the intervention arm had a 31% faster time to recovery (11 days vs. 15 days) (p<0.001)
    - Patients on the intervention arm had a 8% mortality rate vs. 11.6% in the placebo arm (p=0.059)
Further up to date information on treatment options for COVID-19

ACP review-Treatment COVID-19
HOW DO PATIENTS DO?

› The most reported predictors of severe prognosis in patients with COVID-19 included: age, sex, features derived from CT scans, CRP, LDH, and lymphocyte count
  › Other proposed labs: D-dimer, ANC:ALC ratio, troponin T, NT-proNP

› Patients who are active smokers, older, and have co-morbidities have a higher disease severity and mortality
  › Active smokers have a 1.5 times higher risk of severe symptoms and 2.4 times higher risk of ICU admission, mechanical ventilation or death
HOW DO PATIENTS DO?

- 14% develop severe disease requiring hospitalization and oxygen
- 5% require ICU admission
  - 25-30% of hospitalized patients require ICU admission
  - Essentially all secondary to hypoxic respiratory failure
- Mortality can reach 62% for patients in critical care
- Case fatality rate 2.3% China
  - Cases aged 70-79 8.0%
  - Cases older than 80 14.8%
- Case fatality rate 7.2% Italy
  - 20% had active cancer

HOW DO CANCER PATIENTS DO?

- Meta analysis of 11 studies
  - 2% of COVID cases were in cancer patients
- Higher likelihood of severe events (35-54%)
  - Mortality 28.5% in one study, case fatality rate 5.6% vs. 2.3% in the general population
  - Patients with more advanced cancer are more likely to have severe disease
  - Recent treatment (within 14 days) associated w/ development of severe events (HR=4.079)

PART II – JOURNAL ARTICLES
Clinical Characteristics of Coronavirus Disease 2019 in China

Wei-jie Guan, Ph.D., Zheng-yi Ni, M.D., Yu Hu, M.D., Wen-hua Liang, Ph.D., Chun-quan Ou, Ph.D., Jian-xing He, M.D., Lei Liu, M.D., Hong Shan, M.D., Chun-liang Lei, M.D., David S.C. Hui, M.D., Bin Du, M.D., Lan-juan Li, M.D., et al., for the China Medical Treatment Expert Group for Covid-19
WHO ARE THE PATIENTS?

› Median age 47 years, only 0.9% under-age of 15
› 41.9% female
› 23.7% had at least one coexisting illness
  › 0.9% (10 pts) had cancer of any kind
› Patients with severe disease
  › Older by median 7 years
  › Presence of any coexisting illness (39.7% vs. 21.0%)
    › Of the 10 cancer patients - 7 had mild disease, 3 severe

Guan et al, NEJM, February 2020

*Please see supplemental document
HOW DO THEY PRESENT?

- Median incubation period is 4 days
- Symptoms
  - 43.8% Fever on admission with 88.7% developing fever during their hospitalization
  - 67.8% cough, 38.1% fatigue, 33.7% sputum production
- Lack of typical physical exam findings associated with URI
- Imaging
  - 86.2% CT findings, 59.1% CXR findings
- Labs (medians)
  - WBC 4.7 (severe 3.7)
  - Lymphocyte count 1.0 (severe 800)
  - PLT 168 (severe 137.5)
  - Hgb 13.4 (severe 12.8)

Guan et al, NEJM, February 2020

*Please see supplemental document*
WHAT ARE THE CLINICAL OUTCOMES?

- 67/1099 (6.1%) of all patients met composite outcome of ICU admission, mechanical ventilation, or death
  - 43/173 (24.9%) of patients who presented with severe disease met composite endpoint

- Other important complications
  - 12% septic shock
  - 37% ARDS

- Treatments
  - 58% IV antibiotics, 35.8% oseltamivir, 31% antifungals
  - 18.6% systemic glucocorticoids
  - 13.1% IVIG
  - 41.3% required oxygen
  - 6.1% mechanical ventilation
  - 0.5% ECMO
  - 0.8% CRRT

- 55/1099 patients required ICU level care (5%) 
- 15/1099 patients died (1.4%)

Guan et al, NEJM, February 2020

*Please see supplemental document*
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Wenhua Liang, Weijie Guan, Ruchong Chen, Wei Wang, Jianfu Li, Ke Xu, et al.

Published: February 14, 2020  DOI: https://doi.org/10.1016/S1470-2045(20)30095-6
WHAT DID THESE PATIENTS LOOK LIKE?

- 18 (1%) had a history of cancer
- 5 (28%) had a history of lung cancer
- 4/16 (25%) had received chemotherapy or surgery within the past month
- Median age 63 years
- 4/18 (22%) prior smoking history

Liang et al, Lancet Oncology, February 2020

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cancer patients</th>
<th>Non-cancer patients</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>63.1±12.1</td>
<td>48.7±16.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (Male%)</td>
<td>61.1%</td>
<td>57.2%</td>
<td>0.814</td>
</tr>
<tr>
<td>Known smoking history</td>
<td>22.2%</td>
<td>6.8%</td>
<td>0.032</td>
</tr>
<tr>
<td>Any other comorbidity*</td>
<td>22.2%</td>
<td>24.2%</td>
<td>1.000</td>
</tr>
<tr>
<td>Abnormality in X-ray</td>
<td>22.2%</td>
<td>15.2%</td>
<td>0.504</td>
</tr>
<tr>
<td>Abnormality in CT-scan</td>
<td>94.4%</td>
<td>70.8%</td>
<td>0.033</td>
</tr>
<tr>
<td>Polypnea*</td>
<td>47.1%</td>
<td>23.5%</td>
<td>0.039</td>
</tr>
</tbody>
</table>

*: other comorbidities include chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, coronary heart disease, cerebrovascular disease, viral hepatitis type B, malignant tumor, chronic kidney disease and immunodeficiency. *other symptoms being compared but found no difference include fever, cough, expectoration, stuffy nose, conjunctival congestion, headache, sore throat, dyspnea, fatigue, nausea and vomiting, hemoptysis, diarrhea, muscular pain, arthralgia, shivering.
WHAT HAPPENED TO THESE PATIENTS?

- Higher risk for severe events
- Recent treatment associated with more severe events
- Age was only risk factor for severe events
- Cancer patients appear to deteriorate more rapidly

Liang et al, Lancet Oncology, February 2020
WHAT ARE THE AUTHORS RECOMMENDATIONS?

1. An intentional postponing of adjuvant chemotherapy or elective surgery for stable cancer patients in endemic areas.

2. Stronger personal protective provisions should be made for patients with cancer or cancer survivors.

3. More intense surveillance or treatment should be considered when cancer patients are infected with SARS-CoV-2, especially for older patients or in those with co-morbidities.

Liang et al, Lancet Oncology, February 2020
Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China

Clinical Characteristics of Cancer Patients with COVID-19

- 28 hospitalized COVID-19 infected cancer pts from 3 hospitals in Wuhan, China
- 17 (60.7%) male, median age 65
- 25.0% Lung cancer patients, 14.3% esophageal, 10.7% breast
- 28% acquired infection in the hospital
- 82% fever, 81% dry cough, 50% SOB
- 82% lymphopenia, 82% CRP elevation, 75% anemia, 89% hypoproteinemia
- 75% GGOs, 46% patchy consolidation on CT chest
  - Patchy consolidation as associated with a higher risk of severe events (HR 5.438, 95% CI 1.498-19.748, p=0.010)
70% of patients with stage IV disease developed severe symptoms vs. 44.1% of non-stage IV patients (not statistically significant **)

Recent treatment (within 14 days) was associated with severe events HR 4.079 (95% CI 1.086-15.322, p=0.037)

53.6% of all cancer patients had a severe event
   21.4% ICU admission, 35.7% had life threatening complications

78.6% required oxygen, 35.7% required invasive mechanical ventilation

71.4% received some type of antiviral medication
   arborol (50%), lopinavir/ritonavir (35.7%), ganciclovir (32.1%), ribavirin (3.6%)

82% received antibiotics

80% received steroids

28.6% died
Outcome of Oncology Patients Infected With Coronavirus

Abdul-Rahman Jazieh, MD, MPH¹; Thamer H. Alenazi, MD¹; Ayman Alhejazi, MD¹; Faisal Al Safi, MD¹; and Ashwaq Al Olayan, MD¹
19 patients with confirmed cancer diagnosis

- Median age 66, 63% male

- 47% hematologic malignancy, 21% colorectal cancer, 16% lung cancer, 3% other
  - For solid tumors (10/19 pts), 50% were stage IV
  - 90% active disease
  - Active disease was significantly associated with a high fatality rate
  - 1/3 were receiving active treatment
  - No difference in outcomes

- Most common comorbidities included diabetes (52%), hypertension (58%), cardiac disease (47%)

- 80% required ICU admission
  - 81% ARDS, 69% intubated, 56% had renal injury of which 19% required dialysis

- 84% fatality rate, 100% of those with hematologic malignancies and advanced cancer vs. 39% in the general population
Research Letter

March 25, 2020

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Jing Yu, MD1,2,3; Wen Ouyang, MD1,2,3; Melvin L. K. Chua, MBBS, PhD1,4,5; et al

Author Affiliations | Article Information

CANCER PATIENTS IN WUHAN CHINA

- 1524 patients with cancer who were admitted to the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University from 12/30/2019-02/17/2020
- 12 were diagnosed with COVID19
- Infection rate of SARS-CoV-2 with cancer was 0.79% (cumulative incidence of COVID-19 reported in the city of Wuhan 0.37%)
- Median age 66, 66% older than 60
- 58.3% NSCLC
  - Patients with NSCLC older than 60 had a higher incidence of COVID 19 than those younger 4.3% vs. 1.8%
- 42.7% on active treatment
  - with immunotherapy or without immunotherapy (n=3) or radiation therapy (n=2)
  - 3/12 had serious illness, 1/12 required ICU level care, 6/12 discharged, 3/12 died

Yu et al, JAMA Oncol, March 2020
Case report of a NSCLC patient

Case report from China was published in JTO

57 M with advanced EGFR L858R mutant NSCLC on Osimertinib presented with fever, cough, SOB, myalgia, and diarrhea with known exposure to COVID19 and was found to be positive for SARS-CoV-2

Treated with lopinavir/ritonavir

Continued Osimertinib

Improved and was discharged after 1 month of hospitalization

Zhang et al, Journal of Thoracic Oncology, March 2020
Case report of NSCLC on nivolumab

- 65 yo M w/ emphysema and NSCLC dx in 2012 s/p surgical removal of cerebral mets as well as WBRT and systemic carboplatin/pemetrexed until in 7/2013 when he was found to have progressive disease and was started on nivolumab in the s/o clinical trial. He has remained on this since with stable disease.

- On 3/4/2020 he p/w SOB, fever, and mental confusion. Labs on presentation were notable for normal leukocytes with lymphopenia, elevated CRP, transaminases, and LDH. Nasal swab was positive for COVID 19. Within 24 hours he required 15 L/min of supplemental oxygen and sedation for agitation. He passed on 3/9/2020.

- He was not treated with more advanced procedures likely due to his cancer and emphysema history

- Highlights need for oncologist to be involved in the care of their patients sick with COVID for advocacy as well as alternative treatment strategies –the authors in this case offered steroids as a consideration
73 yo M w/ pT2aN0 NSCLC s/p lobectomy in 2016 was noted to have a centimetric nodule in the left superior lobe suspected for malignancy.

PET/CT was ordered and scheduled for 3/18/2029 in Italy.

Patient had no symptoms, COVID19 exposures, and was afebrile.

PET/CT revealed bilateral diffuse intense FDG uptake in the lower lobes, mediastinal lymph nodes, and less intense uptake in the remaining lobes. Uptake corresponded to peripheral predominant GGOs.

Pt was tested w/ RT PCR resulted positive later requiring ICU admission with rapid disease progression and ARDS.
Original Investigation
April 6, 2020

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Giacomo Grasselli, MD1,2; Alberto Zangrillo, MD3,4; Alberto Zanella, MD1,2; et al
Series of 1591 patients with COVID19 requiring ICUs

- Median age 63, 82% male
- 68% had at least 1 comorbidity, 49% HTN, 8% cancer
- 99% required respiratory support
  - 88% mechanical ventilation, 11% non-invasive ventilation
  - Median of FIO2 was lower for younger patients and median PaO2/FiO2 was lower in younger patients
- 1581 had disposition information
  - 58% still in ICU
  - 16% discharged from the ICU
  - 26% died in the ICU
    - Older patients had a higher mortality 36% vs. younger patients 21%
COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, China
From Jan 1-22 the thoracic oncology dept of Tongji Hospital continued routine operations

139 underwent lung resection among these 7 were laboratory confirmed COVID-19 post op

Median age 69, 5 males

Co-morbidities included COPD (2), ILD (1), HL (1)

6/7 NSCLC, 1/7 pulmonary sclerosing pneumocytoma

All 7 had successful, uneventful surgeries

- 4 VATs lobectomy, 1 VATS segmentectomy plus wedge, 1 thoracotomy sleeve lobectomy 1 lobectomy plus bronchus reconstruction
Pathology
- 7 patients had typical malignant pathology
  - Patient 1: wide range of lung interstitial inflammation w/ numerous infiltrating immune cells (predominantly plasma cells/macrofages), thickened alveolar septum and fibrous connective tissue proliferation was noted. Large number of macrophages and fam cells in the alveolar cavities but no evidence pneumocyte hyperplasia was observed, no obvious viral inclusions.
  - Other 6 patients did not have evidence of inflammation

Clinical history
- Oseltamivir was used for all 7, addition of umifenovir in 2 and lopinavir and ritonavir in 1 patient
- 4 received steroids
- 3 patients required intubation and ultimately died
- 2 cured and discharged from the hospital
- 2 hospitalized and stable
Presentation
- All 7 presented with fever after surgery, ranging 0-23 days post op
- 5 endorsed SOB, 4 nonproductive cough, 2 fatigue, 1 productive cough, 2 myalgia, 1 diarrhea

Labs
- Decline in lymphocyte count was observed in all 7, 5 had frank lymphopenia
- 1 had transaminitis
- Elevated CRP and procalcitonin was found in all 7
- 5/7 had elevated d-dimers and fibrinogen

Imaging
- All 7 had emerging GGOs w/ (4) or w/o (3) reticulation
- 3 progressed to bilateral findings
Cancer Discovery

Research Briefs

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Vikas Mehta, Sanjay Goel, Rafi Kabarmti, Daniel Cole, Mendel Goldfinger, Ana Acuna-Villaorduna, Kith Pradhan, Raja Thota, Stan Reissman, Joseph A. Sparano, Benjamin A. Gartrell, Richard V. Smith, Nitin Chn, Madhur Garg, Andrew D. Racine, Shalom Kalnicki, Roman Perez-Soler, Balazs Halmos, and Amit Verma

DOI: 10.1158/2159-8290.CD-20-0516
218 PTs with cancer and COVID-19 infection treated in Montefiore Health System from March 18-April 8

- Median age 69, 58% male
- 28% died
  - 25% of solid tumor patients
  - 55% of lung cancer patients
  - 37% of hematologic malignancy patients
- Active disease (< 1 year) and advanced metastatic disease showed trend toward increased mortality
- Active chemotherapy and radiation therapy were not associated with increased case fatality
- Age and concomitant heart and lung disease were associated with increased mortality
- 61% of those who died had frequent exposure to health care system often due to either living in a nursing home or frequent hospitalizations
- Case fatality rates (see table 4) are higher in all age groups when compared to NYC COVID 19 cases
Table 2: Disease characteristics of cancer patients with COVID-19 and association with mortality

<table>
<thead>
<tr>
<th></th>
<th>Alive (72%)</th>
<th>Deceased (28%)</th>
<th>P Val</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>157</td>
<td>61</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Males</strong></td>
<td>91 (72%)</td>
<td>36 (28%)</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Females</strong></td>
<td>66 (73%)</td>
<td>25 (27%)</td>
<td></td>
</tr>
<tr>
<td><strong>Median Age (Range)</strong></td>
<td>66 (10-92)</td>
<td>76 (10-92)</td>
<td>0.0006</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race</th>
<th>N/Tot Alive (%)</th>
<th>N/Tot Deceased (%)</th>
<th>P Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caucasian</td>
<td>14 (64%)</td>
<td>8 (36%)</td>
<td>0.602</td>
</tr>
<tr>
<td>Hispanic</td>
<td>58 (76%)</td>
<td>18 (24%)</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>67 (73%)</td>
<td>25 (27%)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>5 (71%)</td>
<td>2 (29%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>13 (62%)</td>
<td>8 (38%)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metastasis (Solids only)</th>
<th>N/Tot Alive (%)</th>
<th>N/Tot Deceased (%)</th>
<th>P Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastasis (Solids only)</td>
<td>27 (22%)</td>
<td>15 (78%)</td>
<td>0.06</td>
</tr>
<tr>
<td>Active Cancer (&lt;1yr)</td>
<td>60 (38%)</td>
<td>32 (62%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Active ChemoTx</td>
<td>34 (22%)</td>
<td>8 (39%)</td>
<td>0.07</td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>4 (26%)</td>
<td>1 (74%)</td>
<td>1</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>38 (24%)</td>
<td>11 (76%)</td>
<td>0.33</td>
</tr>
<tr>
<td>DM</td>
<td>53 (34%)</td>
<td>27 (66%)</td>
<td>0.116</td>
</tr>
<tr>
<td>HTN</td>
<td>100 (59%)</td>
<td>47 (41%)</td>
<td>0.047</td>
</tr>
<tr>
<td>Chronic Lung Dis</td>
<td>39 (22%)</td>
<td>28 (66%)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Chronic Kidney Dis</td>
<td>33 (21%)</td>
<td>21 (49%)</td>
<td>0.032</td>
</tr>
<tr>
<td>Coronary Artery Dis</td>
<td>24 (15%)</td>
<td>19 (85%)</td>
<td>0.012</td>
</tr>
<tr>
<td>CHF</td>
<td>18 (11%)</td>
<td>15 (22%)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

Table 3: Lab values of cancer patients with COVID-19 and association with mortality

<table>
<thead>
<tr>
<th></th>
<th>Alive (72%)</th>
<th>Deceased (28%)</th>
<th>P Val</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>157</td>
<td>61</td>
<td>0.048</td>
</tr>
<tr>
<td>Pre-COVID-19 (Mean)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>11.99</td>
<td>11.22</td>
<td>0.048</td>
</tr>
<tr>
<td>Platelet Count</td>
<td>225</td>
<td>256</td>
<td>0.16</td>
</tr>
<tr>
<td>WBC</td>
<td>7.33</td>
<td>7.55</td>
<td>0.12</td>
</tr>
<tr>
<td>ANC</td>
<td>4.9</td>
<td>5.3</td>
<td>0.18</td>
</tr>
<tr>
<td>Total Lymphocyte Count</td>
<td>1.6</td>
<td>1.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Post-COVID-19 (Mean)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>10.7</td>
<td>9.9</td>
<td>0.047</td>
</tr>
<tr>
<td>Platelet Count</td>
<td>177</td>
<td>167</td>
<td>0.7</td>
</tr>
<tr>
<td>WBC</td>
<td>5.8</td>
<td>8.8</td>
<td>0.01</td>
</tr>
<tr>
<td>ANC</td>
<td>4.4</td>
<td>6.6</td>
<td>0.017</td>
</tr>
<tr>
<td>Total Lymphocyte Count</td>
<td>0.7</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Ferritin</td>
<td>1491</td>
<td>2136</td>
<td>0.21</td>
</tr>
<tr>
<td>D Dimer</td>
<td>4.1</td>
<td>8.3</td>
<td>0.002</td>
</tr>
<tr>
<td>Lactate</td>
<td>2</td>
<td>4</td>
<td>0.001</td>
</tr>
<tr>
<td>LDH</td>
<td>438</td>
<td>683</td>
<td>0.01</td>
</tr>
</tbody>
</table>
Table 4: Comparison of Cancer and COVID-19 mortality with all NYC cases (official NYC numbers upto 5pm, April 12th, 2020) and a control group from the same healthcare facility. The NYC cohort and the control group were compared independently to the Cancer-COVID-19 cohort and the P Values and Odds ratio are shown.

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Cancer COVID-19 Cases</th>
<th>Cancer COVID-19 Deaths</th>
<th>%</th>
<th>Control Group Cases</th>
<th>Control Group Deaths</th>
<th>%</th>
<th>Odds Ratio</th>
<th>P Val</th>
<th>NYC Cases</th>
<th>NYC Deaths</th>
<th>%</th>
<th>Odds Ratio</th>
<th>P Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>218</td>
<td>61</td>
<td>28%</td>
<td>1090</td>
<td>149</td>
<td>14%</td>
<td>2.45</td>
<td>8.46E-07</td>
<td>104185</td>
<td>6182</td>
<td>6%</td>
<td>6.160</td>
<td>&lt; 2.2e-16</td>
</tr>
<tr>
<td>0-17</td>
<td>3</td>
<td>1</td>
<td>33%</td>
<td>5</td>
<td>0</td>
<td>0%</td>
<td>na</td>
<td>0.375</td>
<td>2025</td>
<td>3</td>
<td>0%</td>
<td>304.66</td>
<td>0.006</td>
</tr>
<tr>
<td>18-44</td>
<td>13</td>
<td>1</td>
<td>8%</td>
<td>75</td>
<td>2</td>
<td>3%</td>
<td>2.99</td>
<td>0.38466</td>
<td>39704</td>
<td>284</td>
<td>1%</td>
<td>11.56</td>
<td>0.088</td>
</tr>
<tr>
<td>45-64</td>
<td>64</td>
<td>10</td>
<td>16%</td>
<td>320</td>
<td>13</td>
<td>4%</td>
<td>4.35</td>
<td>0.00161</td>
<td>37851</td>
<td>1449</td>
<td>4%</td>
<td>4.65</td>
<td>0.0001</td>
</tr>
<tr>
<td>65-74</td>
<td>59</td>
<td>13</td>
<td>22%</td>
<td>282</td>
<td>41</td>
<td>15%</td>
<td>1.66</td>
<td>0.169939</td>
<td>13128</td>
<td>1511</td>
<td>12%</td>
<td>2.17</td>
<td>0.020</td>
</tr>
<tr>
<td>&gt;75</td>
<td>79</td>
<td>36</td>
<td>46%</td>
<td>408</td>
<td>93</td>
<td>23%</td>
<td>2.83</td>
<td>7.34E-05</td>
<td>11477</td>
<td>2935</td>
<td>26%</td>
<td>2.44</td>
<td>0.0001</td>
</tr>
</tbody>
</table>
RESEARCH BRIEF

Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak

Mengyuan Dai, Xinbo Li, Miao Li, Fuxiang Zhang, Geling Li, Zhan Cheng, Zhan Zhang, Hao Yue, Peng Wu, Qichao Zhang, Yong Xie, Haibin Xiong, Chen Wang, Chengxun Chen, Fei Xiong, Yue Zhang, Yeqin Peng, Guihong Li, Bo Chen, Jingying Ye, Ling Wang, Hao Wang, Ye Li, Yeshen Chen, Jiushua Mao, Xingjie Guo, Zhuyan Li, Xuan Gao, Can Hu, Zhen Li, Yaying Shi, Yiming Qi, Jing Yang, Daniel C. Tener, Li Chen, Lorelei A. Moore, Mauricio Santillana, and Hongbin Cai
105 cancer patients and 536 non-cancer patients treated for COVID-19 in Hubei Province China January 22-February 24, 2020

Lung cancer was most frequent cancer type 20.95%

Treatments
- 13 radiation, 17 chemotherapy, 8 surgery, 4 targeted therapy, 6 immunotherapy

Outcomes
- Higher death rates OR 2.34 (95% CI 1.15-4.77 p=0.03)
- ICU admission OR 2.84 (95% CI 1.59-5.08 p=<0.01)
- Risk of 1 severe or critical symptom OR 2.79 (95% CI 2.79 CI 1.74-4.41 p<0.01)
- Patients with hematologic malignancies had highest death rate, ICU admission rate, risk of severe/critical symptoms, and need for mechanical ventilation followed by lung cancer patients
- Patients with advanced/metastatic disease similarly had higher adverse outcomes
- Pts with on immunotherapy tended to have high rates of death (2/6) and development of critical symptoms 4/6
- Pts s/p surgery tended to have high rates of death (2/8), need for ICU admission (3/8), and need for invasive ventilation (2/8)
- Patients who received radiation did not show statistically significant differences in having any severe events when compared to non-cancer patients
Review

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
Analysis of 909 patients who died of COVID-19 in Italy

- More than 50% had 3 or more comorbid conditions, only 2% had no comorbid conditions
- 16.5% were cancer patients (defined as having been treated within the last 5 years)
  - 95.5% experienced ARDs
  - 25.7% had acute renal failure
  - 11.2% diagnosed with a secondary superinfection
  - 11.6% diagnosed with cardiac injury

Analysis of 9 patients with COVID-19 and cancer

- 3 managed as inpatients (2/3 with severe disease), 6 outpatients
  - None required ICU
- All patients either former or current smokers
- Median age 68, median 1 comorbidity
- 8/9 on active cancer therapy (3-curative, 5-palliative)
  - 4-chemotherapy, 2- experimental immunotherapy, 2 small molecule
  - None of the immunotherapy patients experienced an adverse outcome
CANCER DISCOVERY

Research Briefs

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

Jia Luo, Hira Rizvi, Jacklynn V Egger, Isabel R Preeshagul, Jedd D. Wolchok, and Matthew D. Hellmann

DOI: 10.1158/2159-6290.CD-20-0596
69 consecutive patients with lung cancer between March 12-April 13, 2020

- Median age 69
- 80% active or metastatic disease
- 64% had at least a 5-year pack year smoking history
- 62% required hospitalization
- 24% died
- No significant difference in disease severity regardless of PD-1 blockade exposure when accounting for smoking history
- Smoking history was associated with severe COVID-19

### Tables

| Baseline characteristics and clinical course of patients with lung cancers and +SARS-CoV-2 test |
| --- | --- |
| **Patients characteristics** | **Patients (n = 69)** |
| Age | Median (range) - yr |
| Male | 33/69 (48%) |
| Female | 36/69 (52%) |
| Race |  |
| White | 40/69 (59%) |
| Black | 12/69 (17%) |
| Asian | 11/69 (16%) |
| Other | 2/69 (3%) |
| Unknown | 4/69 (6%) |
| Ethnicity |  |
| Hispanic or Latino | 8/69 (12%) |
| Non-Hispanic or Latino | 57/69 (82%) |
| Unknown | 4/69 (6%) |
| Prior smoking history |  |
| < 5 pack years | 25/69 (36%) |
| ≥ 5 pack years | 44/69 (64%) |
| Lung cancer specific features |  |
| Non-small cell lung cancer | 64/69 (93%) |
| Small cell lung cancer | 5/69 (7%) |
| Metastatic or active lung cancer | 55/69 (80%) |
| Prior thoracic surgery or radiation therapy | 32/69 (48%) |
| Comorbid conditions |  |
| Chronic obstructive pulmonary disease (COPD) | 12/69 (17%) |
| Non-COPD lung disease | 14/69 (20%) |
| Obesity (BMI≥30) | 23/69 (33%) |
| Hypertension | 58/69 (55%) |
| Congestive heart failure | 5/69 (7%) |
| Diabetes mellitus | 21/69 (30%) |
| Clinical course |  |
| Hospitalization | 42/67* (63%) |
| Admission of ICU/Receipt of Intubation/Transition to DNI | 24/67* (37%) |
| Admission to intensive care unit (ICU) | 15/67* (23%) |
| Receipt of intubation and mechanical ventilation | 13/67* (20%) |
| Transition to do not resuscitate/do not intubate (DNR/DNI) | 10/67* (15%) |
| Death | 16/67* (24%) |
Presented by Marina Chiara Garassino, MD

34.6% death rate (66/191) among patients with thoracic cancers

Most frequent complications

- Pneumonia and pneumonitis: 79.6% (125/157)
- ARDS: 26.8% (42/157)
- Multiorgan failure: 7.6% (12/157)
- Sepsis: 5.1% (8/157)

No cancer treatment was associated with a higher mortality

No comorbidities were significantly associated to a higher risk of death
## Cancer characteristics

<table>
<thead>
<tr>
<th></th>
<th>N=137 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Solid tumor</strong>, n=119</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>23 (19.3%)</td>
</tr>
<tr>
<td>Gastro Intestinal (GI)</td>
<td>18 (15.1%)</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>17 (14.3%)</td>
</tr>
<tr>
<td>Genito-urinary (GU)</td>
<td>17 (14.3%)</td>
</tr>
<tr>
<td>Gynecological</td>
<td>17 (14.3%)</td>
</tr>
<tr>
<td>Thoracic</td>
<td>12 (10.1%)</td>
</tr>
<tr>
<td>Dermatology</td>
<td>9 (7.6%)</td>
</tr>
<tr>
<td>Others (endocrine, CNS, ACUP)</td>
<td>6 (5%)</td>
</tr>
<tr>
<td><strong>Hematology</strong>, n=24</td>
<td></td>
</tr>
<tr>
<td>Mature B cell neoplasms/Myeloma</td>
<td>15 (62.5%)/4 (16.7%)</td>
</tr>
<tr>
<td>Acute Myeloid Leukemia (AML)</td>
<td>4 (16.7%)</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3 (12.5%)</td>
</tr>
<tr>
<td>Others (MDS)</td>
<td>2 (8.4%)</td>
</tr>
<tr>
<td><strong>Current Status</strong> (Unk, n=2)</td>
<td></td>
</tr>
<tr>
<td>Remission/Curative intent</td>
<td>56 (41.5%)</td>
</tr>
<tr>
<td>Active advanced disease</td>
<td>79 (58.5%)</td>
</tr>
</tbody>
</table>
Outcome of cancer patients with COVID-19 at Gustave Roussy Cancer Center, presented at ACCR virtual meeting 4/24/2020

SARS-CoV-2 diagnosis and characteristics

- **Diagnosis suspected / symptoms**:  
  - Fully asymptomatic pts, n=31 (23%)  
  - Self-reported symptoms, n=105 (77%)

<table>
<thead>
<tr>
<th>Symptoms at diagnosis (after medical assessment)</th>
<th>N=111 (83%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>65 (47)</td>
</tr>
<tr>
<td>Dry cough</td>
<td>63 (46)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>47 (34)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>45 (33)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>15 (11)</td>
</tr>
<tr>
<td>Anosmia</td>
<td>13 (9.5)</td>
</tr>
</tbody>
</table>

- **Contact with a known Covid-19 patient**:  
  - N=26 (20.5%)

- **Diagnosis confirmed by**:  
  - RT-PCR
  - CT SCAN alone

- Median time to admission, 4 days

* One patient w/o information
12% incidence was comparable to global population. 80% of patients are symptomatic.
11% required ICU admission.
14.8% died (compared to 18.3% in France).

Factors that affect outcomes:
- Frail (ECOG >1)
- Hematologic malignancies
- Patients with advanced disease and treated with cytotoxic chemotherapy within 3 months.
Treatment guidance for lung cancer patients

- Guidelines from JTO
- Guidelines from ESMO
- Guidelines from the Abramson Cancer Center at the Hospital of the University of Pennsylvania
Management of Lung Cancer during the COVID-19 Pandemic

Figure 1. Algorithm for treating patients with Lung Cancer during the COVID-19 pandemic. *Screening Questionnaire detailed in Supplementary Table 1. **Drive through testing preferred (if available) for stable patients. In hospital evaluation for patients with severe symptoms or hypoxia.

Supplementary Table 1. Screening Questionnaire used at UPHS

<table>
<thead>
<tr>
<th>TRAVEL HISTORY OR CONTACT</th>
<th>INFECTIOUS DISEASE SCREENING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Outside the US or to the NYC Metro Area in the past 2 weeks Contact with a Person Under Investigation COVID-19 Testing Pending</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td></td>
</tr>
<tr>
<td>Difficulty Breathing</td>
<td></td>
</tr>
<tr>
<td>Shortness of Breath</td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>Hemorrhage</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: UPHS: University of Pennsylvania Health System
## Management of Lung Cancer during the COVID-19 Pandemic

<table>
<thead>
<tr>
<th>STAGE</th>
<th>RECOMMENDATIONS</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAGE I</td>
<td>Defer surgery for lung nodules &lt; 2cm, GGO, carcinoid tumors</td>
<td>Consider SBRT/ Ablation</td>
</tr>
<tr>
<td></td>
<td>Follow ACS guidelines, and decisions must be based on institutional resources</td>
<td>Consider withholding adjuvant chemotherapy for patients &gt; 75 years of age or with significant comorbidity</td>
</tr>
<tr>
<td>STAGE II/III</td>
<td>Delay adjuvant chemotherapy to 3-4 months post-operatively</td>
<td>Consider Neo-adjuvant/ Induction if surgery not immediately feasible</td>
</tr>
<tr>
<td>STAGE III</td>
<td>Delay start of consolidation durvalumab up to 6 weeks from completion of concurrent Chemo Radiation</td>
<td>Consider delaying start of concurrent Chemo Radiation on case-by-case basis, discuss with Radiation Oncology about sequential chemotherapy followed by Concurrent Chemo Radiation</td>
</tr>
<tr>
<td></td>
<td>Hypo-fractionated RT schedules should be used with concurrent chemotherapy, when feasible</td>
<td>Consider using Q5W chemotherapy regimens, instead of QW chemotherapy to minimize exposure</td>
</tr>
<tr>
<td></td>
<td>No consolidation chemotherapy should be administered after completion of concurrent Chemo Radiation</td>
<td></td>
</tr>
<tr>
<td>STAGE IV</td>
<td>After initial induction chemo-Immunotherapy, consideration should be made to space out interval between maintenance infusions, especially for those who have been on therapy for &gt; 6 months and those with an excellent clinical/ radiographic response</td>
<td>For patients on TIG: Do not routinely hold TKI for Covid-19 positive patients unless symptomatic</td>
</tr>
<tr>
<td></td>
<td>Stop Immunotherapy for patients who have completed 2 years of treatment</td>
<td>If symptomatic and concern for pneumonitis, advise testing for Covid-19 before making a decision about stopping therapy</td>
</tr>
</tbody>
</table>

**Abbreviations:** GGO: ground glass nodules, ACS: American College of Surgeons, SBRT: Stereotactic Body Radiation Therapy, TKI: Tyrosine Kinase Inhibitor
# Management of Lung Cancer during the COVID-19 Pandemic

Table 2. Management recommendations and additional considerations for patients with SCLC by stage of disease

<table>
<thead>
<tr>
<th>STAGE</th>
<th>RECOMMENDATIONS</th>
<th>ADDITIONAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>LS-SCLC</td>
<td>Continue with therapy as planned</td>
<td>Consider BID Radiation Therapy to minimize duration and exposure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Start Radiation Therapy with cycle 2 of chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PCI should be recommended for patients &lt; 75 years of age</td>
</tr>
<tr>
<td>ES-SCLC</td>
<td>Use oral instead of intravenous etoposide on days 1-3 of chemotherapy</td>
<td>Consider oral therapies such as PO temozolomide or PO topotecan for second line platinum</td>
</tr>
<tr>
<td></td>
<td>After induction chemo-immunotherapy, maintenance immunotherapy should be dosed Q4W</td>
<td>resistant, refractory SCLC</td>
</tr>
<tr>
<td></td>
<td>(atezolizumab 1680 mg or durvalumab 1500 mg IV)</td>
<td>Refrain from PCI in consultation with radiation oncology</td>
</tr>
</tbody>
</table>

Abbreviations: BID: Twice Daily, PO: Oral, IV: Intravenous, PCI: Prophylactic Cranial Irradiation
WHAT THE CDC THINKS YOU SHOULD KNOW!

1. Close contact is defined by being within 6 ft of a patient for a prolonged period or having direct contact with infectious secretions
2. Patients with confirmed COVID19 or concern for infection should be isolated in private rooms with a mask and door closed
3. Practice hand hygiene before and after all patient contacts
4. PPE
   1. Respiratory or facemask (respirator for any aerosol generating procedures)
   2. Eye protection
   3. Gloves
   4. Gowns
5. Routine cleaning and disinfection procedures are appropriate for SARS-COV-2
6. You should contact occupational health with any unprotected exposure to a confirmed or possible case or if you develop symptoms yourself.
WHO SHOULD WE BE TESTING?

IDSA:

> **Tier 1**
> - Critically ill patients receiving ICU care with unexplained viral pneumonia or respiratory failure regardless of travel/contact history
> - Any person with fever or signs/symptoms of lower respiratory tract illness and close contact with a confirmed patient within 14 days of symptom onset
> - Any person with fevers or signs/symptoms of lower respiratory tract illness and travel to an endemic area within 14 days
> - Individuals with fevers or signs/symptoms of lower respiratory tract illness who are critical to the pandemic response (i.e., healthcare workers, public health officials, or essential leaders)

> **Tier 2:** hospitalized (non-ICU) patients and long-term care residents with unexplained fever and signs/symptoms of lower respiratory tract infection.

> **Tier 3:** Patients in outpatient setting who meet the criteria for influenza testing.
> - Co-morbid DM, COPD, CHF, age >50, Immunocompromised hosts
> - Pregnant women and symptomatic children with similar risks is encouraged

> **Tier 4:** Community surveillance as directed by public health and/or ID authorities.
WHO SHOULD WE BE TESTING?

CDC:

› Hospitalized patients who have signs and symptoms compatible with COVID-19 in order to inform decisions related to infection control.

› Other symptomatic individuals such as, older adults and individuals with chronic medical conditions and/or an immunocompromised state that may put them at higher risk for poor outcomes (e.g., diabetes, heart disease, receiving immunosuppressive medications, chronic lung disease, chronic kidney disease).

› Any persons including healthcare personnel, who within 14 days of symptom onset had close contact with a suspect or laboratory-confirmed COVID-19 patient, or who have a history of travel from affected geographic areas within 14 days of their symptom onset.
Early stage cancer patients
- Postpone surgery/radiation if able
- Provide appropriate psychological counseling around treatment delay to patient and family via telemedicine
- Recommend consideration of target therapy in adjuvant therapy to avoid side effects of chemo, repeated hospital visits, and immunosuppression

Patients infected with SARS-CoV-2 can resume care after 2 weeks of clinical stability

Prior to surgery or initiation of chemo/radiation a 2-week isolation is required with daily fever and symptom checks

Defer any unnecessary infusions (i.e. zoledronic acid)

Move any possible treatments into the “Day ward” (infusion suite) vs. hospital

Visits and labs to be done at remote centers and telemedicine if possible

Policies to mitigate wait times, PPE available to patients while in the health care system, appropriate barricades to entice patients to travel in low risk parts of the hospital
They do not offer their own set of guidelines, but refer the CDC’s guidelines

- Limit access to the facility through one point of entrance
- Triage stations should be set up outside the facility, clinic, or office with social distancing 6 ft apart to screen patients/visitors for COVID-19 symptoms and fever before entering
- All patients seen in clinic should be screened for potential exposures or symptoms
- All clinics, infusion suites, and waiting rooms should be redesigned with social distancing in mind
- All patients should be informed on COVID 19 associated symptoms and instructed on appropriate hand hygiene
- In the setting of fever a comprehensive fever work up should be performed
- For most patients it is appropriate to continue or initiate routine treatment without anticipatory intensity modifications
- If a patient is confirmed or presumed to be infected, standard treatment delays in the setting of infection should be performed.
  - These patients should be given PPE and separated from other patients if they must be seen in clinic
- Minimize non-essential staff in clinic and ensure adequate supplies of PPE
There is no evidence for prophylactic antiviral therapy for immunosuppressed patients

Delivering as much care as possible remotely
  › Conduct remote check ins for high risk patients

Limit visitors —allow only if essential for care delivery

Recommended strategic use of growth factor to mitigate treatment induced neutropenia

No evidence to support use of PPE in cancer patients on treatment who are not infected

Postpone cancer screening that requires inpatient evaluation (i.e. colonoscopy, mammogram)

Mental health services in the community should be identified and readily made available to patients/providers

To consider:
  › Holding chemo for patients in deep remission on maintenance
  › Switching to oral chemo when possible to minimize clinic visits
  › Arranging infusions at unaffected satellite sites or in the home if possible
  › Holding chemo for 2 weeks for sites within an “infectious hub”
  › Modifying or delaying chemo for high risk patients after a comprehensive risks/benefits analysis
Italy created new clinical pathways for cancer patients

- All for profit elective health care activity was stopped to increase health care access
- Hub and spoke networks established so cancer patients can be triaged to a parallel health system separated from the COVID-19 care centers
  - Public and private care centers have combined their workforce, care-lines, resources
  - Concentrate resources
  - Care is driven by expert consultations

Like prior guidelines

- Delay treatments and direct clinical care when able and appropriate
- Aggressive disease prevention
Considerations from the SSCA experience

› Disease prevention through screening, patient/provider education, and appropriate PPE use/training
› Multilayer coverage system for clinics
› Extending clinic hours and acute evaluation capabilities to triage patients away from ERs
› Delay all non-essential care and rapidly expand telemedicine
   › Defer non-essential consultations (i.e.- second opinions)
› Treatment delays in the non-curative setting
› Treatment delays for cancer surgery when safe alternative neo-adjuvant options are available (i.e.- endocrine therapy in early stage breast cancer)
› Pro-active end of life care discussions with patients who are at high risk for serious illness
   › with input from palliative care, ethics, and other disease site experts when appropriate.
› Remember provider and leadership well-being
Editorial article

Emphasized the “distraction effect” of the pandemic

- The potential negative effect of shifting total attention away from standard clinical care to COVID-19 only
- Potential back-log of delayed and rescheduled cancer care

Avoid, if possible, delaying any curative interventions (surgery, chemo, radiation)

Emphasized the potential negative impact of delaying palliative chemo in terms of symptom control and survival time

Encouraged trying to continue screening activities like mammogram

Francesco et al, Annals of Oncology, March 2020
Ensure the continuum of care

› Cancer service should be delivered but all steps should be taken to protect patients from infection with SARS-CoV-2
  › For most patients the benefit of following a well-planned and well-controlled anti-cancer treatment plan will outweigh the risk of coronavirus infection

› Utilization of new practice models including telemedicine

› Modifying regimen schedules to reduce number of clinic visits (i.e.- three or two weekly as opposed to weekly, oral or subcutaneous vs. IV)

› A “previous day” telephone encounter should be recommended to identify flu-like symptoms

› Good hygiene and use of PPE

› Emotional support for cancer patients will be critical
Communicate with patients and support their mental wellbeing, and help alleviate any anxiety and fear they may have about COVID19.

Minimize face to face contact and practice standard universal precautions and screen all patients for exposures and symptoms.

Ask patients to attend appointments without family.

Minimize time in the waiting area:
  - Encourage patients not to arrive early, text patients when you are ready to see them so they can wait in their car.

Note: symptoms of COVID19, neutropenic sepsis, and pneumonitis may be difficult to differentiate on presentation.

Use Table 1 to help inform priority for systemic treatment considering:
  - level of immunosuppression associated with treatment, patient specific risk factors, capacity issues, risk of cancer not being treated optimally with risk of being immunosuppressed and becoming ill from COVID19.

### Table 1 Prioritising patients for systemic anticancer treatment

<table>
<thead>
<tr>
<th>Priority level</th>
<th>Categorisation based on treatment intent and risk/benefit ratio of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Curative treatment with a high (more than 50%) chance of success</td>
</tr>
<tr>
<td>2</td>
<td>Curative treatment with an intermediate (15% to 50%) chance of success</td>
</tr>
<tr>
<td>3</td>
<td>Non-curative treatment with a high (more than 50%) chance of more than 1 year extension to life</td>
</tr>
<tr>
<td>4</td>
<td>Curative therapy with a low (0% to 15%) chance of success or non-curative therapy with an intermediate (15% to 50%) chance of more than 1 year extension to life</td>
</tr>
<tr>
<td>5</td>
<td>Non-curative therapy with a high (more than 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life</td>
</tr>
<tr>
<td>6</td>
<td>Non-curative therapy with an intermediate (15% to 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life</td>
</tr>
</tbody>
</table>
Try to deliver anti-cancer treatment in different and less immunosuppressive ways
- IV versus oral regimens
- Shorter treatment regimens
- Decrease frequency of immunotherapy regimens
- Providing repeat prescriptions
- Deferring infusions for long term prophylaxis (i.e. zoledronic acid)
- Utilize home delivery of prescriptions
- Using treatment breaks for long term treatments

Decisions should be made in a multi-disciplinary team
Figure 1 – A hypothetical decision tree for the triage of a patient with COVID-19 referred for radiation therapy
French Guidelines

Apply to adult patients with solid tumors

Prevention

Medical and radiation oncology should remain “COVID19 sanctuaries”

Oncology patient's presence at hospitals/clinics should be minimized due to their increased susceptibility

Home infusions, IV-> Oral substitutions, telemedicine, regimen timing adjustment, temporary holidays for patients with metastatic disease

In the hospital/clinic COVID19 patients should be isolated and treated separately from cancer patients

Prioritization (esp. if hospital/clinical resources limited)

(1) patients with cancer managed with curative intent (favoring those <60 yo and/or life expectancy >5 years)

(2) patients with cancers managed with non-curative intent treatments and <60 and/or life expectancy >5 years

(3) other patients with cancer managed with non-curative intent treatments, favoring those who if their disease progresses are at high risk for rapid mortality
Editorial

› Highlights the high-risk nature of cancer patients during the COVID-19 pandemic
  › Need for significant healthcare resources in a time of healthcare overextension
  › Increased vulnerability to infection
  › Many clinical trials are halted
  › Challenges for collaboration and dissemination of new knowledge due to halting research conferences
How we treat patients with lung cancer- review

- All regimens with a survival benefit should be prioritized
- Risk: benefit assessment for adjuvant treatments
- RT concurrent or sequential to chemo with curative intent should be reserved for those with adequate respiratory function
  - Stage III NSCLC RT should start on day 1 of chemo so only 2 cycles will be needed
- Palliative or ablative RT should not be denied if it does not require multiple visits.
  - Tx to the lung should be limited to cases with compression of airways or bleeding
- If patient is COVID19 positive but asymptomatic a 28-day delay should be considered
- 2 negative tests 1 week apart should be performed before restarting treatment
- Regimens with longer intervals and shorter duration should be preferred
- Oral chemo should be considered for high risk patients (ECOG 2, elderly)
- Use of prophylactic granulocyte colony stimulating factor
# How we treat patients with lung cancer - review

## Table 1 Practical suggestions to treat patients with lung cancer during the SARS-CoV-2 pandemic

<table>
<thead>
<tr>
<th>Non-small cell lung cancer</th>
<th>Small cell lung cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Should be started when possible</strong>†</td>
<td>NACT for locally advanced resectable disease‡</td>
</tr>
<tr>
<td></td>
<td>Sequential/concurrent CHT/RT§¶ for stage III disease</td>
</tr>
<tr>
<td></td>
<td>First-line treatment for metastatic disease</td>
</tr>
<tr>
<td></td>
<td>Palliative or ablative radiotherapy (SBRT) outside the lung**</td>
</tr>
<tr>
<td><strong>2. Should not be stopped without justification</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NACT for locally advanced resectable disease‡</td>
</tr>
<tr>
<td></td>
<td>Sequential/concurrent CHT/RT§¶ for stage III disease</td>
</tr>
<tr>
<td></td>
<td>First-line treatment for metastatic disease</td>
</tr>
<tr>
<td><strong>3. Can be given preferentially</strong></td>
<td>CT/RT for stage III disease</td>
</tr>
<tr>
<td></td>
<td>Oral chemotherapy for ECOG PS 2 and elderly patients (instead of intravenous)</td>
</tr>
<tr>
<td><strong>4. Can be withheld or delayed after careful consideration††</strong></td>
<td>Withhold ACHT in patients at significant COVID-19-related risk‡‡</td>
</tr>
<tr>
<td></td>
<td>Delay ICÍ (within 42 days) for stage III disease after CHT/RT</td>
</tr>
<tr>
<td></td>
<td>Withhold maintenance pemetrexed</td>
</tr>
<tr>
<td></td>
<td>Prolong intervals of ICÍ</td>
</tr>
<tr>
<td><strong>5. Should not be started without justification</strong></td>
<td>Third and beyond lines of chemotherapy in patients at significant COVID-19-related risk‡‡</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Regimens with longer interval (including ICÍ; i.e., nivolumab 480 mg every 4 weeks or pembrolizumab 400 mg every 6 weeks) should be preferred.
†NACT could be helpful to bridge time to surgery in case where surgery is not possible.
§In patients with adequate respiratory function.
¶Try to start RT on day 1 of chemotherapy, only two cycles will be needed, three cycles if starting RT with cycle 2, or sequential.
**Exception: indicated if compression of airways or bleeding. Fractions of SBRT could be reduced if organ at risk constraints (from eight fractions to five or three) and palliative RT single or in two fractions (8–10 Gy or 17 Gy, respectively) should be used where possible.
††Patients with family members or caregivers who tested positive for COVID-19 should be tested before or during any cancer treatment, whenever. If a patient results positive and is asymptomatic 28 days of delay should be considered before (re)starting the treatment. In the case of SARS-CoV-2, two negative tests at 1-week interval should be performed before (re)starting the treatment.
‡‡Patients at significant COVID-19-related risk; aged ≥70, with ischaemic cardiac disease, atrial fibrillation, uncontrolled hypertension or diabetes, chronic kidney disease.

ACHT, adjuvant chemotherapy; CHT, chemotherapy; COVID-19, coronavirus disease; ECOG PS, Eastern Cooperative Oncology Group Performance Status; G-CSF, granulocyte colony-stimulating factor; ICÍ, immune checkpoint inhibitor; NACT, neoadjuvant chemotherapy; PCI, prophylactic cranial irradiation; RT, radiotherapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SBRT, stereotactic body radiotherapy.
Letter describing the strategies employed by the Tuscany Tumor Association during the COVID-19 pandemic

Two triage approach to protect patients and providers from infection

1) Phone triage 48 hours prior
   - Has the pt experienced fever, SOB, breathlessness or cough?
   - Has the pt, or household contacts, participated in high risk travel?
   - Has the pt, or household contacts, had any direct contact with people infected with COVID-19?
   - Has the patient, or household contacts, had direct contact with people currently in quarantine?

2) If first screen negative the patient will undergo a second telephone interview in order to schedule home accesses, avoiding unnecessary contacts. Patients are assessed score symptom severity with the PERSONS score and life expectancy with the palliative prognostic score.
   - Based on these scores' patients are given a color green, yellow, or red based on severity and care is triaged based on clinical need.
Cancer Management

- Focus an appropriate resource allocation to allow for ongoing cancer care
- Clear communication and transparency between stakeholders, suppliers, and health organizations about treatment supply lines
- Cancer diagnosis should still be a priority and strategies for safe diagnostic procedures need to be established (i.e. endoscopy in negative pressure rooms)
- Minimize unnecessary foot traffic in clinics
- Screen all patients and providers for symptoms/exposures
- Chemo delays, switching to oral regimens, prolonging regimens on a case by case basis
- Hospitalized cancer pts should be physically separated from COVID-19 pts
- Anticipate limitations in available blood supply
- Adequately address patient distress
Cancer guidelines during the COVID-19 pandemic

› Letter in Lancet Oncology summarizing global recommendations
› Some additional guidelines not discussed above
  › The Society of Surgical Oncology website includes disease site specific resources to help guide decisions
  › European Society of Surgical Oncology (ESSO) advised against seeing patients older than 70 in clinic unless urgent
  › American Society for Radiation Oncology contains a large section on COVID19
  › US FDA, US NCI and EMA have issued guidance on managing clinical trials
  › Global Radiation Oncology Target Response is a paper with 121 contributors with specific advice to guide radiotherapy treatments (i.e. what can be omitted)

https://doi.org/10.1016/S1470-2045(20)30217-5
Framework for prioritizing use of radiotherapy and systemic therapy during COVID-19

› This prioritization scheme still requires
  › Consideration of resources
  › Patient specific risk factors and goals
  › Ability of staff to safely deliver treatment
  › How long a patient has been waiting for care

Higher Priority

- Imminent risk of early mortality
  - Acute leukaemias, aggressive lymphomas, metastatic germ cell tumours

- Potential high morbidity and/or impaired quality of life
  - Radiotherapy for spinal cord compression or opioid-refractory pain crisis owing to bone metastases

- Definitive curative treatments
  - Concurrent chemoradiotherapy for head and neck, cervical, or anal cancers

- Neoadjuvant or adjuvant indications with substantial benefit
  - Adjuvant chemotherapy for stage III colon cancer, chemotherapy and/or radiotherapy for high-risk breast cancer

- Neoadjuvant or adjuvant indications with modest survival benefit
  - Neoadjuvant or adjuvant chemotherapy for bladder cancer, or adjuvant chemotherapy for NSCLC

- Palliative indications with substantial survival benefit
  - Immunotherapy for melanoma, systemic therapy for metastatic breast cancer or metastatic colorectal cancer

- Palliative indications with modest survival benefit and/or major symptom control
  - Palliative chemotherapy for upper gastrointestinal cancers, radiotherapy for bone metastasis unresponsive to other treatments

- Palliative indications without benefits in terms of overall survival or major symptom control
  - Second-line and third-line palliative chemotherapy for many solid tumours

Lower Priority

- Alternative treatments exist or delay does not affect outcomes
  - Bone metastases manageable with medications, prostate cancer appropriate for active surveillance
Perspective piece

Discusses challenges about weighing risks/benefits of cancer treatment during the pandemic

Concern for a bimodal peak of cancer deaths- the immediate spike in those dying from COVID followed by a latent toll of those whose treatments were de-intensified, delayed, or canceled all together
Testing for COVID-19 in lung cancer patients

› Editorial

› Due to the fact lung cancer patients are at higher risk for severe COVID-19 due to age, co-morbidities, structural lung disease, likely prior smoking history, as well as their cancer and its treatment, baseline SARS-COV-2 testing for all patients affected by lung cancer should be recommended

› Also recommends considering bronchoscopy to increase testing sensitivity in the s/o negative RT-PCR and a concerning CT chest w/ or w/o symptoms
Caring for our cancer patients in the wake of COVID-10

› Limit exposure
  › Virtual outpatient visits
  › Virtual assessments of any possible symptoms prior to scheduled chemotherapy, with delayed treatment for those who have possible COVID-19 symptoms
  › Encouraging hand washing and social distancing
  › Restrict visiting on inpatient wards

› Rationalize treatment
  › Prioritize systemic treatment to those who will have most benefit (i.e. curative)
  › Consider treatment delays, especially in high risk patients
  › Prioritization and rationalization of surgeries based on urgency, symptoms, and possibly cure

› Limit morbidity
  › More liberal use of growth factor
  › Early identification of infection with on the door triage/assessments in those w/ fevers or symptoms
  › Delaying all treatments in COVID-positive or query patients
  › Ensure that patients are fully vaccinating
  › Provision of oncological support in decision making for admitted COVID-19 cancer patients
Taking care of older patients with cancer in the context of COVID-19 pandemic

- Letter
- Treatment decisions need to take into consideration cancer type, disease extent, prognosis, and treatment opportunities irrespective of a patient's age
  - *while acknowledging the risks associated with viral infection*
- Evaluation of life expectancy should be part of treatment decision making
- Alternatives to standard therapy that have few side effects on the immune system (i.e. endocrine therapy) should be favored and are preferred to no treatment
- Consider using committees, including ethics, to make treatment decisions

Mourey et al, Lancet Oncology, April 2020
Managing COVID-19 in patients with cancer: a double blow for oncologists

› Editorial

› Cancer patients likely are higher risk for severe COVI-19 as well as higher risk for exposure to the virus

› Multiple practical challenges
  › How to interpret imaging
  › Knowing drug-drug interactions with upcoming COVID-19 treatments
  › Practically considering how to deliver care
How to guarantee the best care to pts with cancer during the COVID-19 epidemic: the Italian experience

- Had to establish an adapted risk communication with updates of statistics related to infected cases and an adjusted level of alert of patients/providers
- PPE and rigorous infection prevention/control measures in clinics
- Three cancer comprehensive cancer center were identified to delivery cancer care in a hub-spoke model
- Widespread patient education about the virus and how to protect themselves
- Telemedicine was widely used
- Checkpoint areas for COVID-19 screening were set up prior to access to one of the cancer hospitals
  - Patients of concern were tested and transferred to COVID-19 hospitals
- Continued clinical trials as able, working closely with sponsors to allow for flexibility and elimination of any burdensome procedures/visits with continued close monitoring
How to guarantee the best of care to patients with cancer during the COVID-19 epidemic: the Italian experience

<table>
<thead>
<tr>
<th>Setting</th>
<th>Strategy</th>
<th>Measures</th>
</tr>
</thead>
</table>
| Patients “off treatment” | Prevention  
Symptom-oriented follow-up  
Implement telemedicine follow-up | Education on COVID-19 symptoms to increase patient awareness  
Phone contact with all patients in the epidemic areas to implement social isolation measures  
Suggestion for protection supplies in case of suspect contacts |
| Patients “on treatment” with curative intent | Prevention  
Implement cancer care within a hub-and-spoke network  
Guarantee a “COVID-19-free” clinical pathway in the hub hospital | All measures listed above  
Guarantee the best of care  
Reduce access to hospital for relatives and vendors  
Cancer team using PPE  
Establish checkpoint in the hub to avoid access of infected patients  
Intensify safety monitoring for patients receiving active treatment using telemedicine |
| Patients “on treatment” in the metastatic setting | Prevention  
Implement cancer care within a hub-and-spoke network  
Guarantee a COVID-19-free clinical pathway in the hub hospital | All measures listed above  
Prioritize treatment according to magnitude of clinical benefit that qualifies patient for a specific treatment (e.g., significant overall survival gain and/or substantial improvement in QoL)  
When chemotherapy is recommended, prefer oral treatments to reduce access to hospital  
All patients must be assured of the best home-based supportive care and enhanced symptoms control via telemedicine |

Abbreviations: PPE, personal protection equipment; QoL, quality of life.
How to guarantee the best of care to patients with cancer during the COVID-19 epidemic: the Italian experience

Table 2. Examples of prioritizing cancer treatment: European Society for Medical Oncology model for early breast cancer medical treatment

<table>
<thead>
<tr>
<th>High priority</th>
<th>Medium priority</th>
<th>Low priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant and adjuvant chemotherapy for patients with triple-negative breast cancer</td>
<td>Prefer endocrine therapy and delay surgery for postmenopausal women with stage I cancers, low-intermediate grade tumors, lobular breast cancers, low-risk genomic signatures</td>
<td>Follow-up imaging, restaging studies, echocardiograms, electrocardiograms, and bone density scans can be delayed if patient is clinically asymptomatic or there are clinical signs of response in the neoadjuvant setting</td>
</tr>
<tr>
<td>Neoadjuvant and adjuvant chemotherapy in combination with targeted therapy for patients with HER2+ breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoadjuvant and adjuvant endocrine therapy ± chemotherapy for estrogen receptor+/HER2− breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completion of neoadjuvant chemotherapy (with or without anti-HER2 therapy) that has already been initiated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of standard adjuvant endocrine therapy in pre- and postmenopausal setting Use telemedicine to manage potential toxicity reported by patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation of treatment in the context of a clinical trial, provided patient benefits outweigh risks, with possible adaptation of procedures without affecting patient safety and study conduct</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Safety at the Time of the COVID-19 pandemic: how to keep our oncology patients and healthcare workers safe

- Caregivers who are exhibiting concerning symptoms should be isolated
- No clear guidelines exist regarding when a cancer pt who has tested positive for COVID-19 can resume therapy
  - CDC recommends a two test approach each ≥24 hours apart in the s/o symptom and fever resolution
  - If no testing at least 7 days from initial symptoms and 3 days from last fever
- Anticipate PPE shortages
- Self-care and stress management

Table 1. Recommendations for Oncology Practices During COVID-19

<table>
<thead>
<tr>
<th>Patient Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescreen and screen for COVID-19 symptoms and exposure history via telephone calls or digital platforms</td>
</tr>
<tr>
<td>Develop screening clinics to allow for patients with symptoms to be evaluated and tested in a dedicated unit with dedicated staff</td>
</tr>
<tr>
<td>Convert in-person visits to telemedicine visits when possible</td>
</tr>
<tr>
<td>Limited or no visitor policy</td>
</tr>
<tr>
<td>Limit surgeries and procedures to only essential, urgent, or emergent cases</td>
</tr>
<tr>
<td>Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center</td>
</tr>
<tr>
<td>Switch therapy to oral oncology if equivalent formulation of infusional therapy is available</td>
</tr>
<tr>
<td>Transition outpatient care to care at home whenever possible (e.g., pump disconnection, administration of growth factors, hormone therapy)</td>
</tr>
<tr>
<td>Increase interval between scans or use biochemical markers in lieu of scans</td>
</tr>
<tr>
<td>Provide resources for wellness and stress management for patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Healthcare Worker Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assure appropriate personal protective equipment (PPE) per guidelines</td>
</tr>
<tr>
<td>Create a centralized resource or website to communicate the recommendations to the healthcare workers as guidelines around PPE and workflaws change</td>
</tr>
<tr>
<td>Implement daily screening tools and/or temperature checks</td>
</tr>
<tr>
<td>Telecommute when possible, with limited onsite staff participating in rotations on a daily basis</td>
</tr>
<tr>
<td>Establish clear stay-at-home and return-to-work guidelines</td>
</tr>
<tr>
<td>Provide resources for wellness and stress management for healthcare workers</td>
</tr>
</tbody>
</table>

Cinar et al, JNCCN, April 2020
Recommendations of individualized medical Tx and common AEs for lung ca pts during the outbreak of COVID-19 epidemic

› Focus on infection prevention
› New treatment starts should be made considering tumor burden and the clinical condition of the patient
› For patients with low tumor burden, stable disease, or undergoing post operative chemo or maintenance t/c delaying treatment or switching to oral options where available
› For patients on immunotherapy potential immune related AEs (i.e. pneumonitis) should be considered
   › For patients with stable disease treatment can be postponed or suspended
› Extend restaging exams/scans in patients w/o symptoms
› Patients should be encouraged to monitor their respiratory symptoms as well as report any fevers
› Patients should be encouraged to sleep, eat a health diet, exercise, and participate in wellness exercises
Visit us at www.iaslc.org